Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic balance study of apraglutide in adults with short bowel syndrome and colon-in-continuity
2020-005129-99Phase 2Completed
- Sponsor
- VectivBio
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apraglutide in short bowel syndrome (SBS) and intestinal failure (IF), sponsored by VectivBio. Primary endpoint: Change in absolute energy absorption. Started Dec 2020; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on 2020-005129-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005129-99.